What Simcere Pharma does

Simcere Pharmaceutical Group (先声药业, 2096.HK) is a Nanjing-headquartered, innovation-driven Chinese pharmaceutical company founded in 1995 and listed on the Hong Kong Stock Exchange since 2020 (previously NYSE 2007-2013). The company operates across five therapeutic areas: oncology, neuroscience (CNS), autoimmune, cardiovascular and anti-infection, plus an "other fields" category, with 40+ commercial brands such as Endostar, Sanbexin, Bicun, Iremod, Orencia, Softan, Newanti, and a succession of newer launches (Enweida 2021, Cosela 2022, Xiannuoxin 2023, Enlituo 2024, Ke Weike and En Ze Shu 2025).

Underlying its commercial franchise is an R&D platform anchored by the National Key Laboratory of Translational Medicine and Innovative Pharmaceuticals (Ministry of Science and Technology, 2015), the wholly owned oncology subsidiary Simcere Zaiming, and global R&D centers in Shanghai, Beijing, and Boston. The platform spans multi-specific antibodies (e.g., the TL1A x IL-23p19 bispecific SIM0709), antibody-drug conjugates (SIM0505 anti-CDH6, SIM0613 anti-LRRC15, plus the platform that produced the Ipsen-partnered preclinical ADC), small-molecule oncology (SIM0532 pan-RAS inhibitor, MAP2K-targeting coumarin compounds), and academic partnerships (Stanford Medicine for IPF first-in-class molecules). An in-house pipeline of 50+ innovative candidates is supplemented by in-licensed assets such as rademikibart (from Connect Biopharma) and zemprocitinib (from Lynk).

The business model combines direct domestic commercialization, out-licensing, and in-licensing. Hospital-focused field sales reach 1,900+ Class III hospitals and 17,000+ other Chinese medical institutions, supported by internal manufacturing in Hainan and Shandong. Globally, Simcere monetizes pipeline assets through upfront and milestone payments plus royalties, with the January 2026 Boehringer Ingelheim deal on SIM0709 worth €42M upfront and up to €1,016M in milestones, and a December 2025 $1B preclinical ADC deal with Ipsen serving as the marquee transactions. In-licensing is used to fill the China commercial funnel (Connect, Lynk, GI Innovation, Orencia/Sanbexin/Sanbexin sublingual type in-licensed assets). Disclosed 2025 revenue is approximately $1,105M, with 6,500+ staff across China, the U.S., and Singapore.

Name

Simcere Pharma

Legal name

Jiangsu Simcere Pharmaceutical Co., Ltd.

Website

https://simcere.com

Company type

Public

Founded year

1995

Operating status

Operating

Headcount range

1,001–5,000 employees

Short description

Simcere Pharmaceutical Group (先声药业, 2096.HK) is a Nanjing-based, Hong Kong-listed Chinese pharma company founded in 1995 that develops, manufactures, and commercializes 40+ branded innovative and generic drugs across oncology, neuroscience, autoimmune, cardiovascular, and anti-infection therapeutic areas via hospital sales covering 1,900+ Class III hospitals in China, complemented by global out-licensing.

Ownership category

akta.pro rank

Product category

Branded Pharmaceuticals

NAICS

Pharmaceutical and Medicine Manufacturing (3254), Pharmaceutical Preparation Manufacturing (325412)

SIC

Pharmaceutical Preparations (2834)

akta.pro primary industry

Specialty Care Pharmaceuticals (HLAIAAAB)

akta.pro secondary industries

Ophthalmology Pharmaceuticals (HLAIAAAL), Cardiometabolic Pharmaceuticals (Cardiovascular/Diabetes/Obesity) (HLAIAAAE), Ophthalmology Specialty Pharmaceuticals (HLAIACAK)

Keywords

• Innovative pharmaceuticals
• Oncology drug development
• Antibody-drug conjugates
• Prescription drug manufacturing
• Biopharmaceutical out-licensing

Headquarters

HQ city

Nanjing

HQ country

China

HQ region

Asia

Offices6 records

Markets served

GTM type

B2B

Offering type

Hardware or Manufacturing

Cost components

Technology or R&D, Personnel, Supply Chain, Marketing or Sales, Operations, Infrastructure

Revenue model

1. Pharmaceutical product sales: Direct commercialization of 40+ branded prescription pharmaceutical products across oncology, neuroscience, autoimmune, cardiovascular/anti-infection, and other therapeutic areas via a hospital-focused sales network covering 1,900+ Class III hospitals and 17,000+ other institutions in China.
2. Out-licensing of pipeline assets: Licensing global (ex-Greater China) development and commercialization rights for pipeline assets to multinational pharma partners, generating upfront payments, milestone payments, and royalties. Example: SIM0709 deal with Boehringer Ingelheim (€42M upfront, up to €1,016M in milestones).
3. In-licensing and co-promotion of partner assets: Acquiring exclusive Greater China rights to third-party assets (e.g., rademikibart from Connect Biopharma, zemprocitinib from Lynk Pharmaceuticals) for development and commercialization in the China market, generating milestones and royalties to partners and product revenue domestically.
4. Strategic co-development partnerships: Collaborative R&D agreements (e.g., with Stanford Medicine for first-in-class IPF molecule, with NextCure on CDH6 ADC) where Simcere funds research and acquires 100% of global rights upon success, generating long-term milestone and royalty streams.

Go-to-market motion2 records

Distribution channels5 records

Marketing channels10 records

Core offering

Simcere Pharmaceutical Group is an innovation- and R&D-driven Chinese pharmaceutical company that develops, manufactures, and commercializes branded prescription pharmaceuticals across five therapeutic areas: Oncology, Neuroscience, Autoimmune, Cardiovascular/Anti-infection, and Other Fields. The company sells 40+ commercial brands directly to 1,900+ Class III hospitals and 17,000+ other medical institutions across China, and additionally monetizes its 50+ innovative pipeline candidates through out-licensing, co-development, and in-licensing partnerships with global biopharma (e.g., Boehringer Ingelheim, Ipsen, NextCure, Connect Biopharma, Lynk Pharmaceuticals, Stanford Medicine).

Product overview

Simcere Pharma (先声药业, 2096.HK) operates a multi-brand pharmaceutical product portfolio organized into five therapeutic areas — Oncology, Neuroscience, Autoimmune, Cardiovascular & Anti-infection, and Other Fields — each comprising multiple commercial brand products. The Oncology portfolio includes Endostar®, Jepaso®, Jiebaili®, Sinofuan®, Enlength®, plus the innovative drugs Enweida® (2021) and Cosela® (2022). The Neuroscience portfolio is anchored by Sanbexin™ (including the sublingual edaravone-dexborneol tablet approved in 2025), Bicun®, and Ancozy®. The Autoimmune portfolio features Iremod®, Orencia® (approved 2020), and Yingtaiqing®. Cardiovascular & Anti-infection includes Softan®, OLMETEC PLUS®, ZAILIKE®, Newanti®, and ZAILIN®. The Other Fields portfolio contains Biqi®, Lowvo®, TB-PPD, KeChuanNing®, FANENG®, OUDIJIA®, and DINGAN®. More recent commercial launches include Xiannuoxin® (2023), Enlituo® (2024), Ke Weike® and En Ze Shu® (2025). On top of this commercial portfolio, Simcere operates an investigational pipeline through its subsidiary Simcere Zaiming, including oncology assets SIM0505 (CDH6 ADC), SIM0613 (anti-LRRC15 ADC), SIM0532 (pan-RAS inhibitor), a Stanford-partnered IPF program, the global-rights-out-licensed IBD bispecific SIM0709, co-developed immunology assets like rademikibart (with Connect Biopharma) and zemprocitinib/LNK01001 (with Lynk Pharmaceuticals). The company is supported by manufacturing bases, the National Key Laboratory of Translational Medicine and Innovative Pharmaceuticals, and global R&D centers in Shanghai and Boston.

Differentiator

Problem solved

Functional benefit

Brands

• Enweida® (恩维达): Innovative drug approved in 2021
• Cosela® (科赛拉)
• Xiannuoxin® (先诺欣)
• Enlituo® (恩立妥)
• Ke Weike® (科唯可)
• Enzeshu® (恩泽舒)
• Sanbexin® (先必新)
• Simcere Zaiming (先声再明)

Products and services

• Enweida® (恩维达) Simcere's innovative oncology drug approved and launched in 2021; included in the commercial pharmaceutical portfolio.
• Cosela® (科赛拉) Simcere drug approved and launched in 2022 per company milestones timeline.
• Xiannuoxin® (先诺欣) Simcere drug approved and launched in 2023 per company milestones timeline; received full approval in 2025 per Chinese site milestones.
• Enlituo® (恩立妥) Simcere drug approved and launched in 2024 per the company milestones timeline.
• Ke Weike® (科唯可) Simcere drug approved and launched in 2025 per Chinese site milestones timeline.
• En Ze Shu® (恩泽舒) Simcere drug approved and launched in 2025 per Chinese site milestones timeline.
• Sanbexin® Sublingual Tablets (先必新® 舌下片, edaravone-dexborneol) Sublingual tablet combining edaravone and dexborneol for acute ischemic stroke treatment; received China NMPA breakthrough therapy designation based on Phase 3 trial showing 64.4% of patients achieving mRS score ≤1 at 90 days. Approved and launched in sublingual tablet form in 2025.
• Sanbexin™ (先必新®) - core CNS brand Central nervous system product for stroke treatment; sublingual formulation combining edaravone and dexborneol received breakthrough therapy designation; the brand spans multiple formulations within Simcere's commercial neuroscience portfolio.
• Orencia® Autoimmune brand product within Simcere's commercial autoimmune portfolio; approved in 2020 per company milestones.
• SIM0505 (CDH6-targeted ADC) Investigational antibody-drug conjugate (ADC) targeting Cadherin-6 (CDH6) with a topoisomerase 1 inhibitor payload; being evaluated in Phase 1 for advanced solid tumors with emphasis on platinum-resistant ovarian cancer. Co-developed by Simcere Zaiming and NextCure.
• SIM0613 (anti-LRRC15 ADC) Anti-LRRC15 ADC independently developed by Simcere Zaiming; Phase I clinical trial initiated with first patient enrolled in China on June 2, 2026.
• SIM0532 (pan-RAS inhibitor) Pan-RAS-targeted investigational anti-tumor drug independently developed by Simcere Zaiming; first patient dosed in clinical trial on May 21, 2026.
• SIM0709 (TL1A x IL-23p19 bispecific antibody) Preclinical bispecific antibody for inflammatory bowel disease (IBD) that simultaneously targets TL1A and IL-23p19; demonstrated superior synergistic efficacy over corresponding monotherapies in preclinical cell and animal studies. Licensed to Boehringer Ingelheim for global (ex-Greater China) development and commercialization.
• Rademikibart (anti-IL-4Rα monoclonal antibody) Anti-IL-4Rα monoclonal antibody for atopic dermatitis, asthma, and COPD being co-developed with Connect Biopharma; Simcere holds Greater China rights via exclusive license with up to $110M in milestones plus tiered royalties. Phase 3 reported positive 52-week sustained efficacy and lower conjunctivitis rates versus Dupixent.
• Zemprocitinib (LNK01001, JAK inhibitor) JAK inhibitor for rheumatoid arthritis developed by Lynk Pharmaceuticals; Simcere is the commercialization partner for Greater China. Phase III trial met all primary and key secondary efficacy endpoints with ACR20 response rate of 79.1% vs 39.7% at Week 24.
• First-in-Class IPF Molecule (Stanford Medicine collaboration) First-in-class novel molecule for idiopathic pulmonary fibrosis (IPF) under joint research collaboration with Stanford Medicine's chemical biology laboratories led by professors Chaitan Khosla and Cui Bianxiao; Simcere funds the research and upon successful completion will license the molecule and obtain 100% of worldwide rights.

Quantifiable outcome

• Sanbexin sublingual formulation: 64.4% of patients achieved modified Rankin Scale score of 1 or less at 90 days in Phase 3 trial, supporting breakthrough therapy designation.
• +2 more outcomes

Named customers9 records

Segments3 records

Ideal customer profiles3 records

Technology focussed Yes

API detail

Has API

No

API docs

API detail

Core technology

AI maturity

App detail

Feature5 records

Partnerships

Eleven partnerships are on record, tiered minor, moderate, flagship and major.

• Chinese Polar Research Center (中国极地研究中心)minorStrategic or Co-development Partner · 7 June 2026Deep cooperation agreement signed with Simcere on June 7, 2026 (Chinese-language source). Details of the partnership scope (R&D, healthcare for polar expeditions, etc.) referenced via Chinese website news page.
• Puqi Pharmaceutical (普祺医药)moderateChannel Partner/ Reseller/ Distributor · 1 June 2026Exclusive promotion cooperation agreement for pumecitinib gel (announced June 1, 2026). Simcere Pharmaceutical Group (2096.HK) is the commercial counterparty in Greater China.
• Stanford MedicineflagshipStrategic or Co-development Partner · 29 May 2026Research collaboration agreement signed May 29, 2026 to jointly advance an exploratory study on idiopathic pulmonary fibrosis (IPF). Simcere will fund the exploratory research of a first-in-class novel molecule; upon successful completion, Simcere will in-license the molecule and obtain 100% of global rights to the resulting product. Conducted with Stanford's chemical biology laboratories led by Prof. Chaitan Khosla and Prof. Cui Bianxiao. Represents the second first-in-class original project worldwide between Simcere and Stanford Medicine and supports Simcere's Innovation 2.0 strategy.
• NextCure, Inc. (SIM0505 expansion)majorStrategic or Co-development Partner · 4 May 2026Dose optimization portion of Phase 1 study initiated for SIM0505 in platinum-resistant ovarian cancer patients. Companies are expanding clinical trial sites into Canada and Europe in addition to the U.S. and China; Phase 1 data expected at ASCO 2026.
• Connect Biopharma Holdings LimitedmajorOEM/ Whitelabel/ Licensing Partner · 23 April 2026Exclusive license agreement granting Simcere rights to rademikibart for Greater China, worth up to $110 million in milestones plus tiered royalties. Simcere is running the China Phase 3 trial in moderate-to-severe atopic dermatitis (259 patients, sustained 52-week efficacy) with NDA pending and potential H2 approval triggering the milestone payments. Simcere also presented rademikibart Phase 3 AD data at AAD 2026.
• NextCure, Inc.majorStrategic or Co-development Partner · 21 April 2026Joint development of SIM0505, an antibody-drug conjugate targeting Cadherin-6 (CDH6) with a topoisomerase 1 inhibitor payload, for advanced solid tumors with an emphasis on platinum-resistant ovarian cancer. Phase 1 dose optimization initiated in May 2026; Phase 1 data accepted for poster presentation at ASCO 2026 (June 1, 2026). NextCure holds exclusive global rights outside of China, Hong Kong, Macau, and Taiwan; Simcere Zaiming retains rights within those territories. Clinical trial sites expanded into Canada and Europe in addition to the U.S. and China.
• AlmirallmoderateStrategic or Co-development Partner · 19 March 2026Collaboration in medical dermatology, including treatments for alopecia areata and atopic dermatitis, anchored by Almirall's new Shanghai innovation hub. Almirall is actively developing and commercializing dermatological treatments including a drug in Phase II trials for autoimmune diseases.
• Boehringer IngelheimflagshipOEM/ Whitelabel/ Licensing Partner · 27 January 2026Exclusive global (ex-Greater China) licensing agreement for SIM0709, Simcere's preclinical bispecific antibody targeting TL1A and IL-23p19 for inflammatory bowel disease (IBD). Upfront payment of €42 million plus potential milestone payments up to an additional €1,016 million (~$1.27 billion). Demonstrated superior synergistic efficacy over corresponding monotherapies in preclinical studies. Simcere's second licensing transaction in the autoimmune field. Boehringer assumes global development and commercialization responsibility outside Greater China.
• Lynk PharmaceuticalsmoderateOEM/ Whitelabel/ Licensing Partner · 12 January 2026Commercialization partnership granting Lynk Pharmaceuticals rights to zemprocitinib (LNK01001) in Greater China. Positive Phase 3 topline results in 430 RA patients showed ACR20 of 79.1% vs 39.7% (placebo) at Week 24 (P < 0.0001). Lynk plans formal presentation at an upcoming international scientific conference.
• GI InnovationminorOEM/ Whitelabel/ Licensing Partner · 11 January 2026Technology transfer / licensing deal with China's Simcere valued at 1.146 trillion won for core pipelines (GI-301, GI-101, GI-102), one of multiple deals GI Innovation has signed with global pharma.
• IpsenflagshipOEM/ Whitelabel/ Licensing Partner · 23 December 2025Ipsen announced a $1 billion investment in a Simcere preclinical antibody-drug conjugate (ADC) program. The deal emphasizes Ipsen's strategic focus on advanced biopharmaceuticals in Asia.

Scale indicators8 records

Recent moves12 records

Expansion highlights6 records

Direct peers

• Hansoh Pharmaceutical: Leading Chinese innovative pharma listed in Hong Kong (3692.HK) with a comparable mix of branded generics plus a growing oncology and CNS innovative pipeline; directly comparable in therapeutic area focus, China hospital channel, and HKEX-listed status.
• Innovent Biologics: China-based biopharmaceutical company (1801.HK) developing innovative biologics including PD-1 antibodies and bispecifics; competes in the same oncology and autoimmune therapeutic areas and pursues similar out-licensing/strategic collaboration strategies with global pharma.
• BeiGene (now BeOne Medicines): Global oncology-focused biopharma with deep China roots and a broad hematology/solid tumor pipeline; comparable as a Chinese-origin innovator pursuing both domestic commercialization and global development/licensing.
• Hutchmed (China MediTech): Hong Kong-listed (13.HK) Chinese biopharma developing innovative oncology therapies with global out-licensing deals (e.g., AstraZeneca, Lilly); closely comparable in innovation model and out-licensing strategy from China.
• Akeso: Chinese biopharma (9926.HK) developing innovative antibodies including bispecifics (PD-1/VEGF, PD-1/CTLA-4); closely comparable in bispecific antibody focus and competitive oncology positioning.
• Junshi Biosciences: Chinese biopharma (1877.HK, 688180.SH) with a leading PD-1 (toripalimab) and a deep pipeline of innovative biologics; comparable as a Chinese innovator pursuing global licensing/co-development (e.g., with Lilly and Coherus).

Broad incumbents

• Hengrui Pharmaceuticals: Largest innovative pharmaceutical company in China, listed on Shanghai Stock Exchange, with a broad pipeline across oncology, autoimmune, and other therapeutic areas; overlaps with Simcere's commercial areas but operates at much greater scale.
• Sino Biopharmaceutical: Large Chinese pharmaceutical conglomerate (1177.HK) with diversified branded generics and innovative drug businesses across oncology, hepatology, and respiratory; comparable in therapeutic breadth and HKEX-listed large-cap pharma positioning.
• CSPC Pharmaceutical Group: Major Hong Kong-listed Chinese pharma (1093.HK) with a sizable innovative drug and biosimilar portfolio spanning oncology, CNS, and anti-infection; comparable in therapeutic mix and HK-listed status.
• Fosun Pharma: Diversified Chinese healthcare group (2196.HK, 600196.SH) operating across pharma manufacturing, innovative R&D, and global distribution; comparable in international footprint (Boston office, cross-border licensing) and broad product portfolio.

Market position

Strengths5 records

Weaknesses5 records

Competitive moat5 records

Key risks6 records

Key highlights6 records

Customer concentration

• Xtwitter.com/SimcerePharm
• Facebookfacebook.com/Simcere
• LinkedInlinkedin.com/company/2094945

Compliance3 records

Revenue estimate

Valuation estimate

Number of profiles

Profiles10 records

Subsidiaries3 records

Funding overview

Funding rounds3 records

Investors15 records

Funding detail is available on the Subscription and Enterprise plan.Contact sales →

M&A

Investments10 records

M&A and investment is available on the Subscription and Enterprise plan.Contact sales →

Frequently asked questions about Simcere Pharma